Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has recently announced the approval of hydrochloride erlotinib, which is a self-developed EGFR tyrosine kinase inhibitor [1] - The drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] - It is also indicated for patients with advanced non-small cell lung cancer who have failed previous chemotherapy [1]